NASDAQ: STIM · Industrial Applications and Services · 9 alerts · CIK 1227636
Share price
$1.25Close, Nov 16
Market cap
$97.2M
Shares outstanding
77.73MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Neuronetics, Inc. filings on SEC EDGAR ↗
Neuronetics Insider Jorey Chernett Buys $79.6K of Stock
Jorey Chernett bought 40,000 shares of Neuronetics, Inc. at $1.99 a share, worth $79.6K in total on Nov 9, 2026. Shares held after the trade: 10,306,225 (+0.4%).
Neuronetics Insider Jorey Chernett Sells $4.48M of Stock
Jorey Chernett sold 3,335,411 shares of Neuronetics, Inc. at $1.15 to $2.39 a share (average $1.34) in 5 transactions, worth $4.48M in total between Nov 6, 2026 and Nov 13, 2026. Shares held after the trade: 7,325,577 (-23.0%).
Neuronetics, Inc. entered into an underwriting agreement to sell 18,750,000 shares of common stock at a public offering price of $1.60 per share. The company also granted underwriters a 30-day option to purchase an additional 2,812,500 shares, bringing the total potential gross proceeds to approximately $34.5 million. Net proceeds will be used to repay a portion of outstanding term loans under its Perceptive Credit Facility and for general corporate purposes.
Neuronetics, Inc. entered into an underwriting agreement to sell 18,750,000 shares of common stock at $1.60 per share, with an additional 2,812,500 shares available via an underwriters' option. The company expects to raise approximately $30 million in gross proceeds ($27.7 million net) to repay debt under its Perceptive Credit Facility and for general corporate purposes.
Neuronetics Debt Financing Update with Perceptive Credit Holdings IV, LP
Neuronetics entered into Amendment No. 6 to its existing Credit Agreement with Perceptive Credit Holdings IV, LP to modify certain revenue covenants. The amendment is subject to an optional prepayment of at least $15 million plus interest and fees, and will automatically terminate if conditions are not met by November 30, 2026.
Neuronetics reported 9% revenue growth driven by Greenbrook clinics while pivoting Neurostar to a capital-purchase model to address broader market demand and improve profitability.
Neuronetics, Inc. reported total revenues of $41.96 million for the quarter ended September 30, 2026, a 12.5% increase over the prior year, driven primarily by growth in the Greenbrook segment. The company achieved a quarterly income from operations of $0.54 million compared to a loss of $7.32 million in the prior year, though it maintained a net loss of $1.56 million for the period.
Neuronetics reported Q3 2026 total revenue of $42.0 million, a 12.5% increase year-over-year, driven primarily by 20.1% growth in its Greenbrook clinic segment. The company achieved a significant turnaround in profitability, reporting positive Adjusted EBITDA of $1.9 million and income from operations of $0.5 million compared to losses in the prior year period.
Term
Q3 2026
“This quarter showed our strategy taking hold across our business. We delivered a record third quarter within Greenbrook as well as NeuroStar system sales. This reflects both our revenue cycle management advances as well as the positive reception of our expanded NeuroStar go-to-market options. We also continued to demonstrate our prioritization on profitability and cashflow generation.”
Dan Reuvers, President and Chief Executive Officer of Neuronetics
Neuronetics Insider Jorey Chernett Buys $40.9K of Stock
Jorey Chernett bought 18,000 shares of Neuronetics, Inc. at $2.27 a share, worth $40.9K in total on Oct 30, 2026. Shares held after the trade: 10,620,988 (+0.2%).